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SUMMARY
Embryonic stem cells (ESCs) can self-renew or differ-
entiate into any cell type, a phenomenon known
as pluripotency. Distinct pluripotent states, termed
naive and primed pluripotency, have been described.
However, the mechanisms that control naive-primed
pluripotent transition are poorly understood. Here,
we perform a targeted screen for kinase inhibitors,
which modulate the naive-primed pluripotent transi-
tion. We find that XMD compounds, which selec-
tively inhibit Erk5 kinase and BET bromodomain
family proteins, drive ESCs toward primed pluripo-
tency. Using compound selectivity engineering and
CRISPR/Cas9 genome editing, we reveal distinct
functions for Erk5 and Brd4 in pluripotency regula-
tion. We show that Erk5 signaling maintains ESCs
in the naive state and suppresses progression to-
ward primed pluripotency and neuroectoderm differ-
entiation. Additionally, we identify a specialized role
for Erk5 in defining ESC lineage selection, whereby
Erk5 inhibits a cardiomyocyte-specific differentiation
program. Our data therefore reveal multiple critical
functions for Erk5 in controlling ESC identity.
INTRODUCTION
Embryonic stem cells (ESCs) can self-renew or potentially differ-
entiate into all cell types, a phenomenon known as pluripotency
(Evans and Kaufman, 1981). Distinct pluripotent states, termed
naive and primed pluripotency, have been described (Nichols
and Smith, 2009). Naive ESCs occupy a developmental ground
state characteristic of the preimplantation embryo (Boroviak
et al., 2015), while primed pluripotent cells resemble post-im-
plantation embryonic epiblast poised for further differentiation
(Tesar et al., 2007). Naive pluripotency is marked by expression
of key self-renewal factors such as Nanog, Krueppel-like tran-
scription factors (Klfs), Rex1 (Nichols and Smith, 2009), and
Esrrb (Festuccia et al., 2012). Conversely, primed pluripotency
is characterized by expression of the de novo DNA methyltrans-
ferase Dnmt3b (Figure 1A) (Ficz et al., 2011), the epiblast marker
Fgf5, and lineage priming factor Brachyury (Nichols and Smith,
2009).
Understanding the mechanisms that control naive-primed
pluripotent transitions is fundamental to ESC biology. In this re-
gard, mouse ESCs (mESCs) provide a tractable model, as they
undergo dynamic transition between naive and primed pluripo-
tency when cultured in leukemia inhibitory factor (LIF) and fetal
bovine serum (FBS) (Chambers et al., 2007; Findlay et al.,
2013). LIF-Jak-Stat3 signaling drives expression of naive plurip-
otency genes (Niwa et al., 1998), while autocrine fibroblast
growth factor 4 (Fgf4)-Erk1/2 signaling promotes primed transi-
tion (Kunath et al., 2007). However, beyond these and several
other core pluripotency pathways, the role of protein kinases in
pluripotency regulation has not been systematically evaluated.
Small-molecule screening represents a simple approach to
elucidate kinase regulators of pluripotency. In a screen for
modifiers of the naive-primed transition, we uncover XMD
series compounds, which selectively inhibit the Erk5 kinase
and BET bromodomain family, as drivers of primed pluripotency.
Using rational inhibitor engineering and genome editing, we
deconvolve individual roles of Erk5 and Brd4 in pluripotency
regulation. Erk5 promotes expression of a network of naive
pluripotency factors, which requires kinase activity, upstream
activation by Mek5, and a C-terminal transcriptional domain.
Furthermore, Erk5 signaling potently suppresses the transition
of naive cells toward primed pluripotency and neuroectoderm
differentiation. Finally, we show that Erk5 has a distinct function
in suppressing late-stage cardiac gene expression and cardio-
myocyte development.
RESULTS
A Screen for Kinase Inhibitors that Modulate the
Naive-Primed Pluripotent Transition
In order to systematically explore signaling pathways that con-
trol the naive-primed transition, we developed a quantitative plu-
ripotency assay based on the naive and primed markers Nanog
and Dnmt3b, respectively (Figure 1A). Control inhibitors stabilize
naive and primed pluripotent states as expected; LIF-Jak-Stat3
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inhibition by ruxolitinib and tofacitinib promotes a primed sig-
nature (low Nanog, high Dnmt3b; Figure 1B), while the Fgfr
inhibitors PD173074 and AZD4547 or the Mek1/2 inhibitors
PD0325901 and PD184352 promote a naive signature (high
Nanog, low Dnmt3b; Figure 1B). We therefore exploited this
assay to interrogate a targeted collection of 228 potent and se-
lective kinase inhibitors (http://lincs.hms.harvard.edu) and iden-
tified those thatmodulate the naive-primed transition (Figure 1C).
Kinase inhibitors that stabilize naive and primed states include
many known pluripotency regulators and non-selective com-
pounds (Figure 1D; Tables S1 and S2). However, we prioritized
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Figure 1. Systematic Identification of Ki-
nase Inhibitors that Modulate Naive-Primed
Pluripotent Transition
(A) mESCs cultured in LIF/FBS transitioning be-
tween naive (green) and primed (red) pluripotent
states.
(B) mESCs were treated with the indicated con-
centrations of Jak inhibitors (ruxolitinib and tofa-
citinib), Fgfr inhibitors (PD173074/AZD4547), or
Mek1/2 inhibitors (PD0325901/PD184352). Klf4,
Nanog, Dnmt3b, and Erk1/2 levels were deter-
mined by immunoblotting.
(C) 228 potent and selective kinase inhibitors
were screened at 1 mM for effects on pluripotency
signature. Nanog and Dnmt3b expression was
determined for each inhibitor and images
overlaid. Selected positive control inhibitors are
highlighted.
(D) The Nanog:Dnmt3b ratio for each kinase inhibi-
tor was determined and inhibitors ranked accord-
ingly. Inhibitors found to alter Nanog:Dnmt3b
beyond a 2-fold threshold were identified as drivers
of naive or primed pluripotency. Selected positive
control inhibitors are highlighted.
See also Tables S1 and S2.
XMD8-85, which promotes primed plurip-
otency, for follow-up analysis.
Erk5 and Brd4/BET Have Distinct
Functions in Regulating the Naive-
Primed Transition
Among kinases, XMD8-85 and related
compounds are selective Erk5 inhibitors
(Deng et al., 2011) but also inhibit Brd4/
BET family bromodomains, transcrip-
tional regulators required for Nanog
expression (Di Micco et al., 2014; Horne
et al., 2015; Liu et al., 2014). This could
potentially account for the primed plurip-
otent phenotype obtained with XMD8-
85, which prompted us to deconvolute
the individual functions of Erk5 and
Brd4/BET during the naive-primed transi-
tion. Thus, we rationally engineered two
compounds with reduced Brd4/BET
inhibitory activity, JWG-045 and JWG-
071. In contrast to XMD, which displays
relatively high affinity for Brd4, JWG has significantly reduced
Brd4 affinity but comparable Erk5 affinity (Figure 2A). Accord-
ingly, JWG does not suppress the Brd4 target gene c-Myc, un-
like XMD (Figure 2B). Interestingly, lower concentrations of either
compound series stabilizes c-Myc, which is explained by inhibi-
tion of Erk5-dependent c-Myc phosphorylation and degradation
(English et al., 1998).
We then compared the effects of XMD and JWGon the Nanog/
Dnmt3b pluripotency signature. XMD compounds suppress
Nanog expression (Figure 2C; Figure S1A), consistent with the
role of Brd4 in Nanog regulation (Di Micco et al., 2014; Horne
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et al., 2015; Liu et al., 2014). XMD treatment also promotes
Dnmt3b expression (Figure 2C; Figure S1A), although this is
reduced at 3 mM (Figure 2C) due to loss of cell viability (Fig-
ure S1B). In contrast, JWG compounds engineered for reduced
Brd4/BET inhibition do not alter Nanog expression (Figure 2C;
Figure S1A). However, Dnmt3b protein (Figure 2C; Figure S1A)
or mRNA (Figure S1C) expression is elevated following either
XMD or JWG treatment, suggesting that specific Erk5 inhibition
drives Dnmt3b expression. Congruently, the BET inhibitor JQ1,
which does not inhibit Erk5 (Malik et al., 2015), suppresses
Nanog without Dnmt3b induction (Figure 2D), indicating that
XMD compounds modulate the naive-primed transition via inhi-
bition of both Erk5 and Brd4/BET.
Genome Editing Confirms that Erk5 Functions in
Pluripotency Regulation
Small molecules frequently exert cryptic off-target effects (Bain
et al., 2007), which prompted us to use CRISPR/Cas9 D10A
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Figure 2. Deconvolution of Distinct Func-
tions for Erk5 and Brd4 in Pluripotency
(A) IC50 determination for inhibition of Erk5 and
Brd4 by XMD and JWG compounds.
(B) mESCs were treated with the indicated con-
centrations of XMD and JWG inhibitors, and c-Myc
and Erk1/2 levels were determined by immuno-
blotting (n = 3).
(C) mESCs were treated with 1 mM AZD4547 or
ruxolitinib or the indicated concentrations of XMD
and JWG inhibitors. Nanog, Dnmt3b, and Erk1/2
levels were then determined by immunoblotting
(n = 3).
(D) mESCs were treated with 100 nM JQ1 and
Nanog, Dnmt3b, and Erk1/2 levels determined by
immunoblotting (n = 3).
(E) Erk5 gene targeted mESC clones were gener-
ated using CRISPR/Cas9 D10A. Dnmt3b, Nanog,
Oct4, and Erk5 levels were then determined by
immunoblotting (n = 3).
(F) mESCs were transiently transfected with Cas9
D10A and either control or gRNAs targeting Grb2,
Stat3, or Brd4. Nanog, Dnmt3b, and Erk1/2 levels
were determined by immunoblotting (n = 3).
(G) Deconvolution of the role of Erk5 and Brd4 in
pluripotency regulation.
See also Figure S1 and Table S3.
paired with tandem gRNAs (Ran et al.,
2013) to selectively disrupt the Mapk7
(Erk5) and Brd4 genes. Multiple Erk5/
mESC clones display elevated Dnmt3b
expression, while Nanog remains rela-
tively unperturbed (Figure 2E; FigureS1C),
corroborating our inhibitor data. Impor-
tantly, Erk5 knockout does not influence
the pluripotency master regulator Oct4
(Figure 2E). We were unable to isolate
stable Brd4/ mESC clones (Di Micco
et al., 2014), but we conducted targeted
gene disruption by transient transfection.
Knockout of the key LIF and Fgf signaling
components Stat3 and Grb2 promotes primed and naive plurip-
otency respectively (Figure 2F), providing proof of principle for
this approach. Brd4 knockout suppresses Nanog expression
without altering Dnmt3b (Figure 2F), consistent with effects of
the Brd4/BET inhibitor JQ1 (Figure 2C). We confirm that expres-
sion of Grb2, Stat3, andBrd4 is efficiently disrupted (Figure S1D).
In summary, we provide multiple lines of evidence that Erk5 sup-
presses Dnmt3b and the transition to primed pluripotency
(Figure 2G).
Erk5 Promotes a Naive Pluripotency Network to
Suppresses ESC Priming
Our findings prompted us to examine the influence of Erk5 on the
extended pluripotency network. Employing Erk5/ mESCs re-
expressing Erk5 at endogenous levels (Figure S2A), we find
that Erk5 modestly influences Oct4, while Nanog is subtly but
significantly induced by Erk5 (Figure 3A). However, Erk5 robustly
maintains expression of key naive pluripotency factors Klf2,
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Rex1, and Esrrb following LIF withdrawal (Figure 3A; Figure S2A),
suggesting that Erk5 maintains the naive state even under
conditions favoring the transition toward primed pluripotency.
We tested this directly by examining the primed pluripotency
markers Fgf5 andBrachyury following LIFwithdrawal (Figure 3B).
Fgf5 and Brachyury induction is significantly suppressed by Erk5
(Figure 3B), confirming that Erk5 functions to restrain the naive-
primed transition by a range of molecular criteria.
Erk5 Kinase Activity and Transcriptional Domain Are
Required to Maintain Naive Pluripotency
Erk5 comprises a kinase domain that is phosphorylated and acti-
vated by Mek5, C-terminal autophosphorylation sites, and a
transcriptional activation domain (Akaike et al., 2004). Erk5
expression in Erk5/ mESCs promotes Klf2 induction upon
LIF withdrawal, which requires Erk5 kinase activity (D200A)
and upstream phosphorylation by Mek5 (T219A Y221F; Fig-
ure 3C). The Mek5 inhibitor BIX02189 also suppresses Klf2
expression in wild-type mESCs (Figure S2B). Interestingly, a
truncation that disrupts Erk5 transcriptional activity (1–740) simi-
larly suppresses Klf2 induction. We assessed the effect of these
mutations on Erk5 kinase activity (Morimoto et al., 2007), which is
abolished by mutating the catalytic aspartate (D200A) or the
activation loop motif phosphorylated by Mek5 (T219A Y221F;
Figure 3D). However, truncation of the transcriptional domain
(1–740) does not suppress Erk5 kinase activity (Figure 3D) but
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Figure 3. Erk5 Signaling Stabilizes Naive
Pluripotency and Suppresses Transition to
Primed
(A) Erk5/ mESCs were transfected with empty
vector or Erk5 cDNA and Nanog, Oct4, Klf2, Rex1,
and Esrrb mRNA levels determined by qRT-PCR
following 3-day LIF withdrawal. Data represent
average ± SD (n = 3).
(B) Erk5/ mESCs were transfected with empty
vector or Erk5 cDNA. Fgf5 and Brachyury mRNA
levels were determined by qRT-PCR following
3 days in the presence or absence of LIF. Data
represent average ± SD (n = 3).
(C) Erk5/ mESCs were transfected with empty
vector or Erk5 constructs and Klf2 protein
expression determined by immunoblotting and
normalized. Data are presented as average ± SD
(n = 3).
(D) Erk5/ mESCs were transfected with empty
vector or Erk5 constructs and stimulated with
H2O2, and Erk5 kinase activity was determined.
Erk5 and Erk1/2 expression levels were deter-
mined by immunoblotting. Data represent average
± SD (n = 3). Intervening lanes were removed,
indicated by a dotted line.
(E) Erk5+/+ mESCs were transfected with empty
vector or Mek5DD cDNA. Nanog, Oct4, Klf2, Rex1,
and Esrrb mRNA levels were then determined by
qRT-PCR following 3 days of LIF withdrawal. Data
represent average ± SD (n = 3).
(F) Erk5+/+ mESCs were transfected with empty
vector or Mek5DD, and Fgf5 and Brachyury mRNA
levels were determined by qRT-PCR after 4 or
5 days in the presence or absence of LIF,
respectively. Data represent average ± SD (n = 3).
(G) Stat3 pTyr705, total Stat3, Erk1/2 pThr202/
Tyr204, and total Erk1/2 levels in Erk5+/+ or Erk5/
mESC clones were determined by immunoblotting
(n = 3).
(H) Erk5+/+ and Erk5/ mESCs were treated with
1 mMAZD4547 or ruxolitinib. Nanog, Dnmt3b, Klf2,
Klf4, and Erk1/2 levels were then determined by
immunoblotting. Intervening lanes were removed,
as indicated by a dotted line (n = 3).
See also Figure S2.
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fails to rescue Klf2 expression in Erk5/ mESCs (Figure 3C),
indicating that Erk5 kinase activity and transcriptional activity
are critical for the maintenance of naive pluripotency.
Mek5 Signaling to Erk5 Potently Stabilizes the Naive
State to Block the Transition to Primed Pluripotency
We hypothesized that constitutive Erk5 activation is sufficient
to robustly stabilize naive pluripotency and suppress a transition
to the primed state. To explore this possibility, we exploited a
constitutively activate Mek5 mutant, Mek5 S313D/T317D (here-
after Mek5DD). Mek5DD expression has relatively minor effects
on Oct4 but robustly maintains key naive markers Nanog, Klf2,
Esrrb, and Rex1 following LIF withdrawal (Figure 3E), indicating
that Erk5 pathway activation promotes the naive state. Thus,
we tested whether Mek5DD suppresses the transition of mESCs
toward the primed state. Fgf5 and Brachyury induction following
LIF withdrawal is robustly suppressed by Mek5DD expression to
a level approaching that observed in mESCs cultured in LIF (Fig-
ure 3F). In addition, we find that Mek5DD expression upon LIF
withdrawal delays Fgf5 induction (Figure S2C), indicating that
Erk5 pathway activation alters kinetics of the naive-primed tran-
sition. Our data therefore provide compelling evidence that Erk5
signaling modulates pluripotency genes so as to inhibit and/or
delay the transition of ESCs from naive pluripotency to the
primed state.
Erk5 Functions in Parallel with LIF/FGF Signaling
We then asked whether Erk5 modulates the prominent pluripo-
tency pathways LIF and Fgf (Figure 1B). Analysis of Stat3 and
Erk1/2 phosphorylation indicates that Erk5 does not directly
modulate LIF or Fgf signaling (Figure 3G). Furthermore, Jak
and Fgfr inhibitors promote primed and naive pluripotency sig-
natures in Erk5+/+ or Erk5/ mESCs (Figure 3H), confirming
that Erk5 does not modulate transcriptional responses to these
key pathways. Indeed, endogenous Erk5 does not prevent loss
of Klf4 expression following LIF deprivation (Figure S2D),
although Erk5 overexpression in Erk5/ mESCs can maintain
Klf4 expression following LIF withdrawal (Figure S2E). Therefore,
although Erk5 modulates Klf4, it does not directly impact LIF
signaling.
Erk5 Maintains Naive Pluripotent ESC Morphology and
Restrains Neuroectoderm Differentiation
Our demonstration that Erk5 drives a naive pluripotent signature
prompted us to examine Erk5/ mESC morphology. Erk5/
mESC colonies stain positive for alkaline phosphatase (AP; Fig-
ure 4A), confirming that these cells are pluripotent. Analysis of
mESC colony morphology indicates that Erk5+/+ mESCs preva-
lently display a ‘‘domed,’’ naive morphology, while Erk5/
mESC lines primarily form flattened, primed colonies (Figure 4B;
Figure S3A). Importantly, Erk5 does not affect the proliferation or
survival of mESCs (Figure S3B).
We next examined whether Erk5 controls pluripotent exit and
ESC differentiation. Culture of ESCs as embryoid bodies (EBs)
mimics differentiation of pluripotent cells during development.
We employed a panel of mESC lines generated by CRISPR/
Cas9 (control Erk5+/+ mESCs, three independent heterozygous
Erk5 clones expressing a short N-terminally truncated Erk5
[Erk5DN/], and three independent Erk5/ mESC clones; Table
S3) and examinedmolecular markers of twomajor differentiation
pathways: Brachyury, a mesendoderm marker, and Sox1, a
marker of neuroectoderm. Sox1 is significantly increased in
Erk5/ EBs (Figure 4C), suggesting that Erk5 suppresses ESC
differentiation to neuroectoderm. In contrast, Brachyury induc-
tion in EBs is unaffected by Erk5 status (Figure 4C), suggesting
that Erk5 specifically controls pluripotent exit toward the neuro-
ectoderm lineage.
Erk5 Controls Cardiomyocyte Differentiation
Independent of Pluripotency Regulation
Developmental genetics indicate that Erk5 plays a key role in
cardiovascular development (Sohn et al., 2002; Yan et al.,
2003), which prompted us to examine the role of Erk5 in cardio-
myocyte differentiation. Remarkably, we observe a significantly
increased percentage of Erk5/ EBs displaying a ‘‘beating’’
phenotype compared to EBs expressing Erk5 (Figure 4D) or
Erk5/ EBs re-expressing Erk5 (Figure S3C). We addressed
the specific developmental stage(s) at which Erk5 influences car-
diomyocyte differentiation (Figure 4E). Interestingly, Erk5 does
not influence EB differentiation to Brachyury+ mesendoderm
(Figure 4C) or induction of the cardiovascular progenitor markers
Pdgfra and Flk1 (Figure 4F), suggesting that Erk5 function during
cardiomyocyte differentiation is distinct from its role in pluripo-
tency regulation. Fluorescence-activated cell sorting (FACS)-
based quantification of cardiovascular progenitor populations
reveals a subtle increase in specification of Pdgfra+/Flk1+ car-
diac and Pdgfra/Flk1+ endothelial precursors in Erk5/ EBs
(Figure 4G), Accordingly, Erk5/ EBs significantly increase the
expression of late-stage cardiac-specific genes, including the
master regulator Nkx2.5 (Tanaka et al., 1999) and the key cardiac
physiology genes troponin T (Tnt) and natriuretic peptide a
(Nppa) (Figure 4H). EB morphology is similar between Erk5+/+
and Erk5/ mESCs (Figure S3D). Our data therefore identify a
key function for Erk5 in restricting cardiac-specific gene expres-
sion and cardiomyocyte differentiation, which is distinct from
both the cardiovascular phenotype observed in Erk5/ mice
(Regan et al., 2002; Yan et al., 2003) and Erk5 function in regu-
lating naive-primed transition in ESCs.
DISCUSSION
In this study, we develop a small-molecule screen and identify
XMD8-85 as a driver of the naive-primed transition. XMD series
compounds inhibit Erk5 kinase and BET bromodomain family,
and we use rational engineering to deconvolute the function of
Erk5 in pluripotency regulation. Orthogonal confirmation using
CRISPR/Cas9 genome editing technology provides compelling
evidence that Erk5 is a key regulator of pluripotency.Wepropose
that this workflow presents a robust and adaptable method to
confirm novel targets identified by small-molecule screens in
biological systems.
Erk5 kinase activity promotes a key network of naive pluripo-
tency factors, including Klf2, Essrb, and Rex1, which suppresses
the transition of naive cells toward primed pluripotency. Interest-
ingly, a C-terminal region of Erk5 not required for kinase activity
is essential to maintain naive pluripotency. Phosphorylation of
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Figure 4. Erk5 Controls Neuroectoderm and Cardiomyocyte Specification of Differentiating ESCs
(A) Alkaline phosphatase staining of Erk5+/+ and Erk5/ mESC colonies.
(B) Analysis of colony morphology of Erk5+/+ and Erk5/ mESC colonies. Data represent average ± SD (n = 3).
(C) Relative mRNA expression of Brachyury and Sox1 were determined for Erk5+/+, Erk5DN/ (three independent clones) and Erk5/ (three independent clones)
mESCs. Data represent the average of all clones ± SD from a representative experiment (n = 3).
(legend continued on next page)
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this region drives nuclear localization (Dı´az-Rodrı´guez and Pan-
diella, 2010; In˜esta-Vaquera et al., 2010) and transcriptional acti-
vation in concert with the Mef2- and/or Sp-family transcription
factors (Kato et al., 1997; Sunadome et al., 2011; Yan et al.,
2001), suggesting a mechanism by which Erk5 promotes naive
pluripotency. Intriguingly, Sp1 and Mef2 transcription factors
function to modulate Klf expression downstream of Erk5 (Mori-
kawa et al., 2016; Parmar et al., 2006; Sunadome et al., 2011).
We also reveal that Erk5 plays a role in cardiac specification,
which was not previously appreciated from in vivo studies
(Sohn et al., 2002; Yan et al., 2003). Failure to elaborate proper
vasculature around the heart causes the lethality observed in
Erk5/ mice, suggesting that Erk5 may function as a develop-
mental switch to ensure cardiovascular cell types are appropri-
ately specified. Our data therefore argue that Erk5 has indepen-
dent functions in maintaining naive pluripotency and controlling
lineage allocation of differentiating cells. Future investigations
will focus on identifying the apparently distinct mechanisms by
which Erk5 controls pluripotency and cardiovascular develop-
ment. Furthermore, our data suggest that Erk5 activators and
small-molecule inhibitors are useful tools to modulate cell fate
during regenerative approaches such as somatic cell reprog-
ramming and directed differentiation.
EXPERIMENTAL PROCEDURES
Many reagents generated for this study are available by request at the MRC-
PPU reagents website (https://mrcppureagents.dundee.ac.uk/).
Antibodies and Chemicals
Antibodies used were Nanog (ReproCell Inc.), Dnmt3b (Imgenex), Klf4 (R&D
Systems), Erk1/2 and Oct4 (Santa Cruz Biotechnology), phospho-p44/42
MAPK (Erk1/2 Thr202/Tyr204), Stat3a, phospho-Stat3 (Tyr705) and c-Myc
(Cell Signaling Technology), Erk5 (Division of Signal Transduction Therapy,
Dundee, UK), Klf2 (Millipore), CD309 (Flk1) APC, Clone Avas 12a1, and
CD140a (PDGFRa) PE, Clone APA5 (eBioscience). AZD4547, PD173074,
PD0325901, PD184352, ruxolitinib, and tofacitinib were from the DSTT
(Dundee, UK). The 228 kinase inhibitor library was curated by the Gray lab
(http://lincs.hms.harvard.edu). JWG-071 and JWG-045 were synthesized by
the Gray lab.
mESC Culture, Transfection, and Lysis
mESCs were cultured on gelatin coated plates in media containing LIF, 10%
fetal calf serum (Gibco), and 5% knockout serum replacement (Invitrogen) un-
less otherwise stated. mESCs cells were transfected using Lipofectamine LTX
(Life Technologies) and selected with puromycin for 48 hr. For CRISPR/Cas9,
mESCs were transfected with pX335 and pKN7 (Addgene) and selected, then
either lysed or clones isolated. To generate stable lines, Erk5/mESCs were
electroporated with 30 mg linearized pCAGGS vector, plated at clonal density,
and clones were analyzed by immunoblotting. Cell extracts were made in lysis
buffer (20 mM Tris [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1% NP-40 [v/v], 0.5%
sodium deoxycholate [w/v], 10 mM b-glycerophosphate, 10 mM sodium pyro-
phosphate, 1 mMNaF, 2 mMNa3VO4, and Roche Complete Protease Inhibitor
Cocktail Tablets).
Nanog/Dnmt3b Pluripotency Screen
3 3 103 mESCs were seeded in 96-well plates and 1 mM inhibitors applied for
48 hr. Cells were lysed, and clarified extract was transferred onto a nitrocellu-
lose membrane using a 96-well vacuum dot blot manifold and immunoblotted
for Nanog and Dnmt3b using Li-Cor 800nm anti-rabbit (Nanog) and anti-
mouse-HRP (Dnmt3b), respectively.
Erk5 Gene Sequencing
Genomic DNAwas extracted using the DNeasy Blood and Tissue Kit (QIAGEN),
and the Erk5 gene was analyzed by PCR sequencing (forward: 50-AGCT
GATCCCGACTGTGTCT-30, reverse: 50-CAGGTGGCCATCAAGAAGAT-30).
mESC Phenotyping
mESCs were cultured at 1,000 cells per six wells for 6–7 days prior to AP
staining solution. For colony phenotyping, mESCs were plated at 200 cells
per 10-cm dish and analyzed after 7 days. For proliferation assay, mESCs
were seeded at 10,000 cells per six wells and counted.
Embryoid Body Differentiation
EBs were formed by aggregating 60,000 mESCs/ml in the absence of LIF for
4 days before transfer to gelatin-coated plates for an additional 4 days.
Fluorescence Activated Cell Sorting
At day 4, EBs were treated with VEGF (5 ng/ml; Peprotech), Activin A (4 ng/ml;
R&D), and BMP4 (0.5 ng/ml; R&D) and dissociated at day 7 by incubation with
TrypLE (Invitrogen) and stained.
RNA Extraction and qPCR
RNA was extracted using the OMEGA total RNA kit and reverse transcribed
using iScript reverse transcriptase (Bio-Rad). qPCR was performed using
SsoFast EvaGreen Supermix (Bio-Rad). The DCt method using GAPDH as
a reference gene was used to analyze relative expression and the 2-DDCt
(Livak) method used to normalize to control. Primers used are listed in
Table S4.
Erk5 Immunoprecipitation Kinase Assay
Erk5 was immunoprecipitated from mESC lysate using 5 mg anti-Erk5 anti-
body. Beads were washed three times in lysis buffer containing 0.5M NaCl,
then resuspended in a total volume of 25 ml kinase assay buffer (50 mM Tris
HCl [pH 7.5], 0.1 mM EGTA, 10 mM MgCl2, 2 mM DTT, and 0.1 mM [g-
32P]-
ATP [500 cpm/pmol]) and incubated at 30C for 30 min. The assay was termi-
nated by SDS sample buffer and heating and analyzed by SDS-PAGE and
autoradiography.
Recombinant ERK5 Kinase Assay
200 ng pure active ERK5 was incubated with the indicated inhibitor in 50 mM
Tris-HCl (pH 7.5), 0.1 mM EGTA, and 1 mM 2-mercaptoethanol. The reaction
was initiated by adding 10 mM magnesium acetate, 50 mM [g-32P]-ATP (500
cpm/pmol), and 250 mM PIMtide (ARKKRRHPSGPPTA) and incubated at
(D) Percentage of EBs displaying beating areas derived from Erk5+/+, Erk5DN/, and Erk5/ mESCs. Data represent the average of all clones ± SD from a
representative experiment (n = 3).
(E) Scheme outlining stages of cardiac differentiation.
(F) Relative mRNA expression of Pdgfra and Flk1 was determined for Erk5+/+, Erk5DN/, and Erk5/mESCs. Data represent the average of all clones ± SD from a
representative experiment (n = 3).
(G) FACS quantification of Pdgfra+/Flk1+ cardiac and Flk1+ endothelial progenitors recovered from each cell line. A representative FACS plot illustrating the
distinct populations is provided. Data represent average ± SD from a representative experiment (n = 3).
(H) mRNA expression levels of Nkx2.5, Tnt, and Nppa were determined for Erk5+/+, Erk5DN/, and Erk5/mESCs. Data represent the average of all clones ± SD
from a representative experiment (n = 2).
See also Figure S3.
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30C for 20 min. The assay was terminated by applying the reaction mixture
onto p81 paper and incorporated radioactivity measured.
AlphaScreen Brd4-1 Bromodomain Binding Assay
Brd4-1 binding assay was performed by Reaction Biology Corp. using
His-tag Brd4-1 proteins expressed in Escherichia coli and biotinylated
acetylated peptides. Brd4-1 protein and inhibitors were preincubated for
30 min in 50 mM HEPES (pH 7.5), 100 mM NaCl, 0.05% CHAPS, and
0.1% BSA, then incubated for a further 30 min after addition of tetra-acet-
ylated histone H4 peptide (H4 (1-21) K5/8/12/16(Ac)4-Biotin) and the strep-
tavidin-coated donor beads. Ni-chelate acceptor beads were added and
incubated for 1 hr, and signals were measured by Envision (Ex/Em = 680/
520–620 nm).
Statistical Analysis
Data are presented as the averagewith error bars indicating SD. Statistical sig-
nificance of differences between experimental groups was assessed using a
Student’s t test. Differences in averages were considered significant if p <
0.05. Representative western blots are shown.
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